- Home
- NRXP vs SER Comparison
NRXP vs SER Comparison
Compare NRXP & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRXP | SER |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.7M | 42.0M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | NRXP | SER |
|---|---|---|
| Price | $2.36 | $3.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $30.50 | $13.00 |
| AVG Volume (30 Days) | ★ 446.3K | 17.2K |
| Earning Date | 11-17-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $242,000.00 | $116,000.00 |
| Revenue This Year | N/A | $134.46 |
| Revenue Next Year | $643.59 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.15 | $3.28 |
| 52 Week High | $6.01 | $7.92 |
Technical Indicators
Market Signals| Indicator | NRXP | SER |
|---|---|---|
| Relative Strength Index (RSI) | 45.23 | 30.89 |
| Support Level | $2.22 | $3.68 |
| Resistance Level | $2.51 | $4.26 |
| Average True Range (ATR) | 0.19 | 0.26 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 68.52 | 1.94 |
Price Performance
Historical ComparisonAbout NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.